"No vaccine manufactured or developed in India has ever received Emergency Use Authorisation or full licensure form the USFDA,” it said in a statement.
Synopsis
Hyderabad-based Bharat Biotech said on Wednesday that a report on a recent study that compared the level of antibodies produced by Covishield and Covaxin after their first and second doses contained “flaws.”
As reported by ET, it found that both vaccines Covishield and Covaxin work well.
Hyderabad-based Bharat Biotech said on Wednesday that a report on a recent study that compared the level of antibodies produced by Covishield and Covaxin after their first and second doses contained “flaws.”
The company also said it will be conducting phase-4 trials of Covaxin. Phase-4 trials are conducted after regulatory approvals to monitor long-term safety and effectiveness of drugs in real-world usage situations.
The Pfizer vaccine, which is manufactured in collaboration with German Biotechnology firm BioNTech, is the only vaccine currently being administered to children in a few countries.
The Delhi government has been at loggerheads with the Centre of supplies of Covid vaccines. Now the state has received over 1.2 lakh of Covishield and 20,000 additional doses of Covaxin.